AHEAD OF THE CURVE ®

The Generalist’s Guide to Vetting a SMID Cap Biotech Company

Overview

In this report, the Cowen biotech team reviews what we see as the three major components of valuing a smid-cap biotech company: valuation methodologies, modeling probabilities of success, and building market models. Of note – the Cowen biotech team does not segregate coverage by market cap.

Valuation methodologies do not rely on specialist knowledge. The major differential from other sectors is a heavier focus on strategic M&A value.

Our research analysts dissect and detail the main parts of analyzing small and mid-cap biotech companies:

  • – valuation methodologies
  • – determining probabilities of success
  • – building a therapy’s market model
  • – decision points where it’s most useful to consult specialists/KOLs/experts including assessing mechanistic rationale, trial statistics, amenable patient populations, reimbursement hurdles, and probability of approval for programs with mixed data

Contact

Headshot DB

Dierk
Beyer

Partner
M&A, Cowen

+49 69 5060 675 62
Email

Order report

    Get the full report.

    Similar Insights

    Image Pharma Services Report May 22
    Pharma Services Report April
    Insights Cowen Valued-Based Care Health Care Business Model Transformation